Acta Neuropsychiatrica

04/07/2024

We will go fully OA in 2025!

Learn more on the future publishing landscape! We will keep all efforts to removing publishing barriers. Acta Neuropsychiatrica welcomes research papers from all over the world and will continue to foster an inclusive .

Access the website for more info: https://www.cambridge.org/core/journals/acta-neuropsychiatrica

College of Neuropsychopharmacology

27/06/2024

📢 New research alert! In a real-world clinical setting, IV ketamine treatment showed effectiveness in reducing depressive symptoms even with complex patients, but it didn't translate to fewer hospitalizations.

https://doi.org/10.1017/neu.2024.18

Join the discussion on clinical trials of fast-acting antidepressants!
Check the paper to discover further factors and clinical challenges when implementing IV ketamine treatment in clinical practice

21/06/2024

New study by Le et al. from Roger McIntyre group reveals a complex relationship between BMI, cognitive health, and inflammation in post-COVID-19. Lower BMI was linked to better cognitive test scores, while higher BMI correlates with increased inflammation markers.

🔗 https://doi.org/10.1017/neu.2024.16

20/06/2024

Glad to see the impact of Machado et al.'s work in Acta Neuropsychiatrica.

Their study shows changes in gene expression linked to synapse plasticity and energy balance in the hippocampus after CBD treatment. A decrease in electron transport and ribosome biogenesis transcripts was observed, with an increase in chromatin modifications and synapse organization.

For full insights, check the paper: https://www.cambridge.org/core/journals/acta-neuropsychiatrica/article/abs/cannabidiol-modulates-hippocampal-genes-involved-in-mitochondrial-function-ribosome-biogenesis-synapse-organization-and-chromatin-modifications/4EAFDEADD9CE649EB313577BA1048C68



Pesquisa inédita da Unicamp identifica mudanças em milhares de genes

20/06/2024

Delighted by the diversity at the Educational Psychiatry Symposium organized by Aarhus University’s Translational Neuropsychiatry Unit and Clinical Psychiatry department.

Great to see many SCNP members as speakers & participants.

The journal welcomes submissions, from original research to reviews.

We are now part of the neuroscience peer review consortium.

Check the website for more info: https://www.cambridge.org/core/journals/acta-neuropsychiatrica

13/06/2024

⭐️Exciting News from Acta Neuropsychiatrica: A Leap in CiteScore Rankings!
We are thrilled to announce that Acta Neuropsychiatrica has achieved a remarkable milestone in its journey towards academic excellence.

🏆Our latest CiteScore now stands at an impressive 8.5, placing us 10th out of 51 journals in the Neuroscience category and 66th out of 567 in Psychiatry and Mental Health journals. This achievement is not just a number—it’s a testament to the quality and impact of the work published by our dedicated authors and the trust placed in us by the scientific community.

📊CiteScore metrics play a pivotal role in enriching the evaluation of serial titles, offering transparent data that accurately measures the citation impact of journals. It’s a tool that supports responsible research assessment, ensuring that the hard work of researchers is recognized and rewarded.

💡Moreover, CiteScore metrics, when combined with qualitative input, provide a balanced, multi-dimensional view that is crucial for decision-making. Whether you’re considering where to submit your next paper or looking for the most influential research in your field, these metrics serve as a reliable guide.

📚We are proud to contribute to the advancement of neuroscience and mental health research and look forward to continuing our tradition of publishing groundbreaking studies that make a real difference.

🥰Thank you to all our contributors, readers, reviewers and associate editors for making this possible.

🧠As you contemplate the next home for your research, consider Acta Neuropsychiatrica: https://www.cambridge.org/core/journals/acta-neuropsychiatrica

07/06/2024

After this week's debates on and in recognition of , we share this recent paper by Rachel Yehuda's group. Combat veterans often show behavioral changes. This study found harassment during deployment correlated with higher suicidal ideation and lower testosterone levels. Read more on:

https://www.cambridge.org/core/journals/acta-neuropsychiatrica/article/interplay-of-combat-deployment-harassment-testosterone-concentrations-and-postdeployment-suicide-risk-in-male-veterans/BA6C5FA2E2392FF131D00ADDBE523D57

05/06/2024

In light of the FDA discussion on M**A therapy for PTSD, did you know its psychostimulant response is mediated by the endocannabinoid system?

Check this paper of Pedro Gobira et al. on Acta Neuropsychiatrica for more info on the topic!

https://www.cambridge.org/core/journals/acta-neuropsychiatrica/article/abs/roles-of-cannabinoid-cb1-and-cb2-receptors-in-the-modulation-of-psychostimulant-responses/C71AF6073038233F0BD57C65526E3959?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark

**A

Roles of cannabinoid CB1 and CB2 receptors in the modulation of psychostimulant responses - Volume 36 Issue 2

04/06/2024

📢 Exciting News: Acta Neuropsychiatrica Joins the Neuroscience Peer Review Consortium (NPRC)!

We are thrilled to announce that the journal has become a member of the Neuroscience Peer Review Consortium (NPRC). This collaboration brings together a network of neuroscience journals committed to enhancing the peer review process for original research reports in the field.

What is NPRC?
The NPRC is a cross-publisher alliance that facilitates efficient and rigorous peer review within the neuroscience community:
1. Cross-publisher seamless access submission: It comprises multiple neuroscience journals that accept manuscript reviews from participating journals.
2. Streamlined Peer Review: reduce the time and effort involved in the peer review process while maintaining high standards of quality in good journals.
3. Author Flexibility: if your paper is not accepted in one journal, you have the option to submit your manuscript to a second participating journal within the consortium.
4. No Additional Cost or Work: there are no additional costs or administrative burdens for authors, reviewers, or editors. Instead, it provides a significant payoff by streamlining the review process and ensuring that valuable feedback is leveraged effectively.

This initiative contributes to a collaborative ecosystem by sharing expertise across journals, enhancing the quality and speed of peer review while maintaining rigorous standards.

We look forward to receiving reviews through NPRC contributing to the advancement of neuroscience research 🌟

Check Acta Neuropsychiatrica website for more information! https://www.cambridge.org/core/journals/acta-neuropsychiatrica

31/05/2024

SCNP 62nd Annual Congress live!
Winner of the 'SCNP Prize for best Poster' announced.
We are pleased to award the 2024 prize to Klara Danielsson for her talk: ''Selective manipulation of striatal dopamine'.
Scandinavian College of Neuropsychopharmacology University of Gothenburg

30/05/2024

SCNP 62nd Annual Congress live!
Winner of the 'Young Scientists Symposium' announced.
We are pleased to award the 2024 prize to Eleonora Genovese for her talk: 'A Macrobiotic Approach to Ameliorate "Chemo-brain" and Chemotherapy-induced Sickness'
Scandinavian College of Neuropsychopharmacology, University of Gothenburg
Translational Neuropsychiatry Unit

30/05/2024

SCNP 62nd Annual Congress live!
'Young Scientists Symposium',
(left to right): Andreas Göteson, Klara Danielsson, Eleonora Genovese, Daniela Atanasovski, ShokouhArjmand, Feride Ayten Eren
Scandinavian College of Neuropsychopharmacology, University of Gothenburg

30/05/2024

SCNP 62nd Annual Congress live!
Andreas Reif talks about 'New treatment options in TRD: hope or hype?'
Andreas Reif Scandinavian College of Neuropsychopharmacology University of Gothenburg

30/05/2024

SCNP 62nd Annual Congress has started.
Mikael Landén talks about whether Bipolar Disorder is neuroprogressive.
https://scnp.org/annual-meeting/2024/programme

Scandinavian College of Neuropsychopharmacology University of Gothenburg

28/05/2024

Check out the last issue of Acta Neuropsychiatrica!
https://sh1.sendinblue.com/ad9x9jtbwlpfe.html?t=1716917708

20/05/2024

🧠 Electroconvulsive therapy (ECT) stands as a cornerstone in the treatment of severe or treatment-resistant depression. A recent systematic review by Toffanin et al. investigated the effects of ECT on brain cortical thickness in major depression.

🔍 Discover the regions that exhibit the most pronounced increases in cortical thickness post-ECT. Could these changes serve as a biomarker for clinical response? What mechanisms may be involved in the ECT antidepressant response?

🌐 Access the paper to find out more and contribute to the topic.

https://www.cambridge.org/core/journals/acta-neuropsychiatrica/article/effects-of-electroconvulsive-therapy-on-cortical-thickness-in-depression-a-systematic-review/A24721FF925B4F99867B65E9EACEEE9D

📄 Acta Neuropsychiatrica is open for both regular and open-access submissions. Don’t miss out on our reduced-fee policy!

13/05/2024

🤲New Insights into the connection of OCD and the Kynurenine Pathway

Discover the pioneering research of Dr. Elif Ozkok’s group in Acta Neuropsychiatrica in their new study, “Investigation of the effects of oxidative stress, inflammation on the pathway of tryptophan/kynurenine in OCD”!

The Tryptophan/Kynurenine Pathway, crucial for brain function and metabolism, is regulated by the Aryl Hydrocarbon Receptor (AhR) transcription factor, which needs the transcriptional activation of the CYP1A1 gene.

🔥Oxidative stress and inflammation may influence this pathway in OCD, with genetic and environmental factors at play.
🧬Variations in AhR and CYP1A1 genes affect the pathway’s balance (regulatory molecules as TBARS, IDO and IFNγ and tryptophan levels), which can be related to OCD.

The group found that:
📈Increased TBARS and IDO activities and decreased tryptophan in individuals with certain AhR genotypes.
📈In the OCD group, TBARS and IDO activities were found to be increased, and tryptophan levels were decreased in those carrying certain allele variations of the CYP1A1.

🌟This pioneering study is the first to demonstrate the influence of IFNγ cytokine and oxidative stress on the Kynurenine Pathway in OCD patients related to CYP1A1 and AhR genetic variants.

Read the full paper and explore the possibilities for new therapeutic strategies in OCD treatment.

Access the Paper: https://www.cambridge.org/core/journals/acta-neuropsychiatrica/article/investigation-of-the-effects-of-oxidative-stress-inflammation-on-the-pathway-of-tryptophankynurenine-in-ocd/65B84F351B38713EC7052C6FBA183A09

07/05/2024

📢 Last Call for Abstracts! Don’t miss the opportunity to present your research at the Scandinavian College of Neuropsychopharmacology.

https://scnp.org/annual-meeting/2024

Enjoy special discounts and apply for our prestigious award if you’re a young investigator. Connect, collaborate, and contribute to the conversation on the latest advances and cutting-edge investigations in neuropsychopharmacology. Submit now and be part of shaping the future of mental health science!

01/05/2024

📅Take advantage of the deadline extension for submitting an abstract to the Scandinavian Society of Neuropsychopharmacology 2024 annual meeting.✨

Reasons why you shouldn’t miss this opportunity:

💊🔍Workshop on Drug Discovery: Learn more on patents and industry insights in psychiatry;

🗣️Timely Debates: Engage in discussions about treatment efficacy and explore new approaches in Major Depression, Psychosis, ADHD, and Drug Abuse Disorders investigation;

🌐🤝Connect with Experts: Network with young clinicians, researchers, and esteemed experts;

🏆💸Discounted Fee: Register now and save! Plus, don’t miss the chance to win the Young Scientist Award.

Register at https://scnp.org/annual-meeting/2024

29/04/2024

Join us for an enlightening journey into the future of psychiatry with the Scandinavian Society of Neuropsychopharmacology's educational workshop.

Engage with pioneering minds like Christian von Holt of Janssen Pharmaceuticals, and Henrik Sjölander, esteemed patent attorney at Barker Brettell.

Be part of critical discussions on drug discovery and patent intricacies in psychiatry, integrating industry insights into clinical trials.

This is your chance to shape the conversation and advance your career among experts in Neuropsychopharmacology. We strongly encourage the participation of young clinicians and postdoctoral researchers.

Don't miss this opportunity to be at the forefront of psychiatric innovation.

Register at https://scnp.org/annual-meeting/2024

Discount fee and Young Scientist Award registration until the 30th of April!

25/04/2024

🗓️Deadline Approaching!

Don´t miss the chance to discuss neuropsychopharmacology cutting-edge research at the SCNP Annual Meeting! Don’t just attend—make an impact!

🔍Discounted Registration Fees: Take advantage of early bird discounts! Register now and save.

🏆Young Scientist Award: Calling all PhD students and postdocs! Submit your abstract for a chance to win the prestigious Young Scientist Award (EUR 2000K for use in research).

🧠💡Exciting Program: Explore the latest breakthroughs, network with experts, and engage in stimulating discussions.

🔗 Learn More & Register at https://scnp.org/annual-meeting/2024

22/04/2024

📢 Join us at the SCNP 2024 Annual Meeting! 🌟

🔬 Lecture Spotlight: “Treatment Resistance in Psychotic Disorders” 🗣️ Speaker: Dr. Ingrid Melle, Head of the Department of Adult Psychiatry at the Institute of Clinical Medicine, University of Oslo, Norway.
🔍 Research Focus: Clinical development of schizophrenia and bipolar disorder, emphasizing clinical trajectories and treatment response.

Be part of the conversation! Submit your abstract!

👉 Check the full program and register in the SCNP Annual Meeting 2024
https://scnp.org/annual-meeting/2024

19/04/2024

15/04/2024

Mark your calendar and register now for the Educational Symposium in Psychiatry, scheduled for June 20, 2024.
https://tnu.au.dk/symposium2024

08/04/2024

🌟 Join us in SCNP 2024 during this Spring! 🌟
https://scnp.org/annual-meeting/2024
🗓️ 29-31th May📍 Location: Gothenburg

🎙️ Lecture Title: “Is Bipolar Disorder Neuroprogressive? Insights into Brain Structure, Cognition, and Biomarkers from Longitudinal Investigations”

🏢 Speaker: Professor Mikael Landén, MD, PhD Institute of Neuroscience and Physiology, University of Gothenburg, Sweden

🌐 About the Lecture: Professor Landén leads a multidisciplinary research team exploring bipolar disorder. At SCNP 2024, he will present groundbreaking findings that both support and challenge the neuroprogressive notion of bipolar disorder. Don’t miss this opportunity to gain insights into the latest research on neuropsychopharmacology!

📢 Enroll in SCNP2024 and mark your calendars. Let’s advance our understanding of bipolar disorder together! 🧠💡

04/04/2024

Aggressive behaviours associated with M**A and psychedelics: a narrative review | Acta Neuropsychiatrica | Cambridge Core

🌟🧠We are excited to share a new narrative review on Psychedelics research. This review explores the monoamine neurotransmitters interplay in aggression when influenced by illicit substances. Intriguingly, not all drugs of abuse lead to aggressive behavior.

🍄Psychedelic compounds, in particular, might be different than other recreational drugs. The study highlights:

✍️A nuanced approach and control for confounding variables
Findings were mixed, in particular for Psychedelics (check results!) and the review challenges the practice of grouping classic psychedelics and empathogens altogether.

🔍Future Steps
To gain a deeper understanding, future studies must confront common limitations:
Polysubstance use complicates the assessment of specific effects.
Pre-existing mental health conditions can be confounding and should be carefully considered.
Stay tuned for more insights as we explore the fascinating interplay between mind-altering substances



🔗 Read the full review https://www.cambridge.org/core/journals/acta-neuropsychiatrica/article/aggressive-behaviours-associated-with-mdma-and-psychedelics-a-narrative-review/F60A68B2469A73C9367A8BDB708D6889

Image: Designed by Freepik

26/03/2024

🌟 Exciting Announcement for SCNP 2024! 🌟

We are thrilled to welcome Dr. Andreas Reif, a distinguished figure in the field of psychiatry, to the Scandinavian Society of Neuropsychopharmacology (SCNP) Annual Meeting.

As the head of the Department of Psychiatry, Psychosomatic Medicine and Psychotherapy at the University Hospital Frankfurt, Dr. Reif is at the forefront of precision psychiatry, using predictive markers to advance treatment methods.

In his much-anticipated lecture titled “New treatment options in TRD: hope or hype?”, Dr. Reif will discuss the latest developments and their potential to transform the landscape of treatment-resistant depression (TRD).

Join us to uncover whether the emerging therapies in Neuropsychopharmacology. Don’t miss out on this insightful session that promises to spark conversation and inspire innovation.

📅 Date: 29-31 May📍 Location: Gothenburg

https://scnp.org/annual-meeting/2024

22/03/2024

Acta Neuropsychiatrica announces a call for submissions to a special issue titled "Progress in Immunopsychiatry," dedicated to showcasing the latest advancements in the field.
https://www.cambridge.org/core/journals/acta-neuropsychiatrica

💡 Immunopsychiatry has significantly advanced our understanding of the link between the immune system and mental health, revealing how immune dysregulation can impact psychiatric disorders.

📊 This issue aims to cover a wide range of topics, from preclinical science to cutting-edge overviews of new drugs in clinical trials to comprehensive epidemiological studies, underscoring the relevance in the pathophysiology of neuropsychiatric disorders.

We invite researchers to contribute original articles and review papers that provide fundamental insights into both clinical and preclinical studies, with a particular emphasis on novel findings in disease mechanisms. Final submissions are due August 1st 2024 on the Journal submission site.

Express interest in the issue here: https://forms.office.com/e/EziJCUGUk9

📝 Check out the website for more information!

06/03/2024

Special Issue call for papers from the journal Acta Neuropsychiatrica on Progress in Psychopharmacology. Guest edited by Giulia Treccani, University of Marburg, Germany and Todd Gould, University of Maryland School of Medicine, USA. Final submissions due 1 Aug 2024. https://cup.org/3wRDJ0j

26/02/2024

🚨Alert on Acta Neuropsychiatrica new Special issue "Progress on Psychopharmacology"

https://www.cambridge.org/core/journals/acta-neuropsychiatrica

📊We invite researchers to contribute original articles and review papers that provide fundamental insights into both clinical and preclinical studies, with a particular emphasis on novel findings in drug mechanisms of action, development, and treatment outcomes. This issue aims to cover a wide range of topics, from preclinical science to cutting-edge overviews of new drugs in clinical trials to comprehensive pharmacoepidemiological studies, underscoring their significance in the treatment of neuropsychiatric disorders.

📝Check out the website for more information!